JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96

Benzinga Newsdesk www.benzinga.com Positive 75.5%

Neg 0% Neu 0% Pos 75.5%

JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $91 to $96.